Arrowhead Pharmaceuticals Inc. (ARWR) Announces Proposed 4M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Arrowhead Pharmaceuticals Inc. (ARWR) Prices 4M Share Offering at $58/Sh
December 4, 2019 6:01 AM ESTArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts. The offering is expected to close on or about December 6, 2019, subject to customary closing... More
Arrowhead Pharmaceuticals (ARWR) Trades at Low, Down 8.5%
December 2, 2019 10:57 AM ESTArrowhead Pharmaceuticals Corp (NASDAQ: ARWR) Trades at Low, Down 8.5%
... MoreArrowhead Research (ARWR) PT Raised to $81 at Chardan Capital Markets
November 29, 2019 7:10 AM ESTChardan Capital Markets analyst Keay Nakae raised the price target on Arrowhead Research (NASDAQ: ARWR) to $81.00 (from $45.00) while maintaining a Neutral rating.
The analyst commented, "In the six weeks since the Company hosted its R&D Day on October 18, 2019, ARWR has increased 92%, driven by a number of catalysts. First, the Company reported encouraging data from the first 12 chronic hepatitis B patients treated with a triple combination... More
